NOTRELOAD AI
  • NOTRELOAD AI
  • Stocks BUZZ.
  • #TrumpTrade
  • 24-HOUR Pass →
  • Invest ↗
Sign in Subscribe
Already have an account? Sign in.

ARS Pharmaceuticals Neffy Nasal Spray Approved in Japan

Japan approved neffy (epinephrine nasal spray). This needle-free option treats severe allergies (anaphylaxis) in adults and kids (>15 kg). It's the first in Japan, offering a compact, injection-free alternative. Availability starts late 2025.

09/19/2025 · 10:17 AM
SPRY
/ Don't stop with just one post.

Related↓

Aquestive Therapeutics Faces FDA Setback for Anaphylm Drug Approval
01/09/2026 · 9:03 AM

Aquestive Therapeutics Faces FDA Setback for Anaphylm Drug Approval

Aquestive Therapeutics stock plunges after FDA identifies deficiencies in Anaphylm application, a sublingual film treatment for severe allergic reactions.

/ Subscriber only
/ Read more

Feed↓

FDA Approves KRESLADI: First Gene Therapy for Rare, Life-Threatening Childhood Immune Disorder
Featured/ 03/27/2026 · 7:18 AM

FDA Approves KRESLADI: First Gene Therapy for Rare, Life-Threatening Childhood Immune Disorder

The FDA has approved KRESLADI, Rocket Pharma’s one-time gene therapy for children with severe LAD-I — a rare, life-threatening immune disorder.

/ Subscriber only
TripAdvisor Stock Gets BofA Upgrade: Activists + Big Hidden Value
03/27/2026 · 6:54 AM

TripAdvisor Stock Gets BofA Upgrade: Activists + Big Hidden Value

BofA upgrades TripAdvisor to Buy and raises price target to $15.

/ Subscriber only
Better Home & Finance Stock Rises on New Crypto Mortgage Deal
03/26/2026 · 5:08 PM

Better Home & Finance Stock Rises on New Crypto Mortgage Deal

Better Home & Finance partners with Coinbase to let you pledge Bitcoin or USDC as collateral for your down payment — without selling your crypto. Fannie Mae-backed mortgages now make it easier for crypto owners to buy a home.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe